Fundraising FoxOsage University Partners — 2019 Investments
6 investments dated 2019 · listed companies and verified rows first · show all
Algorithmia offers an enterprise AI platform for developing, deploying, and governing machine learning models and AI applications, with tooling tailored to roles across data science, engineering, DevOps, and IT teams.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSeattle, US
Kenneth F. Daniel(Executive Officer, Director)Diego M. Oppenheimer(Executive Officer, Director)in
BoardTimothy Porter(Director)inAnna Patterson(Director)in
Co-investorsGradient VenturesMadrona Venture GroupOUP (Osage University Partners)Norwest Venture PartnersWork-Bench
HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery.
HealthtechMedical DevicesLexington, US
Carl Vause(Executive Officer, Director)inMira Sahney(Executive Officer, Director)inDavid Myung(Director)
BoardMichael Hawkins(Director)Wende Hutton(Director)inWilliam Harrington(Director)in
Co-investorsCanaan PartnersOUP (Osage University Partners)Treo Ventures, LlcJohnson & Johnson Innovation – JJDC
Vertically-integrated machine learning platform for healthcare powering transition to value-based care with predictive analytics.
Co-investorsMindset VentureOUP (Osage University Partners)Polaris Partners
San Diego, US
Bob Kain(Executive Officer, Director)inDawn Barry(Executive Officer)inJoseph C. Beery(Executive Officer, Director)
Co-investorsARCH Venture PartnersBain Capital VenturesF-Prime CapitalIllumina Ventures
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieDeerfield Management CompanyJJDC+4 more
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).
BiotechHealthtechMedical DevicesSouth San Francisco, US
John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)inRob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)
Co-investorsOUP (Osage University Partners)Vivo CapitalLumira VenturesRA CapitalRed Tree VentureSBI Investment
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.